PIPELINE
Overview

Medinno Inc. is developing Thrombin pre-conditioned Wharton’s Jelly-derived Mesenchymal Stem Cells (HIEstem) for brain diseases of new borns, such as hypoxic ischemic encephalopathy (HIE) and intraventricular hemorrhage (IVH). Adult Human Neural Stem Cells (ahNSCs) are for adult brain diseases including spinal cord injury (SCI) and stroke. Medinno Inc. is continuously developing new cell therapeutics for various brain diseases by scientific research.

Division Pipeline Project Code Indication Non-clinical Phase Ⅰ Phase Ⅱ BLA
Stem Cell
Therapeutics
HIEstem MS1901 Hypoxic Ischemic
Encephalopathy
MS2001 Intraventricular
Hemorrhage
Adult Human Neural Stem Cell MS2002 Spinal Cord Injury
MS2101 Stroke
Gene therapy
using
Stem Cell
Multiple Sclerosis
Brain Tumor
Division Pipeline Project Code Indication
Stem Cell
Therapeutics
HIEstem MS1901 Hypoxic-Ischemic
Encephalopathy
Non-clinical Phase Ⅰ Phase Ⅱ BLA
Division Pipeline Project Code Indication
Stem Cell
Therapeutics
HIEstem MS2001 Intraventricular
Hemorrhage
Non-clinical Phase Ⅰ Phase Ⅱ BLA
Division Pipeline Project Code Indication
Stem Cell
Therapeutics
Adult Human Neural Stem Cell MS2002 Spinal Cord Injury
Non-clinical Phase Ⅰ Phase Ⅱ BLA
Division Pipeline Project Code Indication
Stem Cell
Therapeutics
Adult Human Neural Stem Cell MS2101 Stroke
Non-clinical Phase Ⅰ Phase Ⅱ BLA
Division Project Code Indication
Stem Cell
Gene
Therapeutics
Multiple sclerosis
Non-clinical Phase Ⅰ Phase Ⅱ BLA
Division Project Code Indication
Stem Cell
Gene
Therapeutics
Brain Tumor
Non-clinical Phase Ⅰ Phase Ⅱ BLA
맨위로